Published in Cancer Weekly, September 23rd, 2003
The delisting notice was received as a result of the company's failure to file its quarterly report on Form 10-Q for the period ended June 30, 2003, as required by NASDAQ Marketplace Rule 4310(c)(14). This delay arises out of the previous announcement of possible accounting irregularities involving the company's accounts receivable and discrepancies relating to the amounts capitalized to date on the company's GeneBank asset.
The company intends to consider its options with respect to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.